Another patient has died from acute liver failure after receiving Sarepta’s gene therapy for DMD ; After a quiet start to the ...

The collaboration revenue from net sales of zurzuvae was $36.1 million for the full year 2024 and $13.8 million for the first ...

Recent health headlines spotlight Surgery Partners rejecting Bain Capital's offer, the U.S. betting on China's drug potential ...

Sage Therapeutics shares gained 0.4% to trade at $9.11 on Tuesday. These analysts made changes to their price targets on Sage ...

Eli Lilly has confirmed plans for a $1.3 billion takeover bid for Verve Therapeutics, upgrading a collaboration between the ...

Calm returned to Wall Street on Monday, and U.S. stocks rose, while oil prices gave back some of their initial spurts ...

Calm returned to Wall Street on Monday, and U.S. stocks rose, while oil prices gave back some of their initial spurts following Israel’s attack on Iranian nuclear and military targets at the end of ...

Migraine and stroke are two common and heterogeneous neurovascular disorders responsible for a significant burden for those affected and a great economic cost for the society. There is growing ...

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations ...

Calm returned to Wall Street on Monday, and U.S. stocks rose, while oil prices gave back some of their initial spurts ...

The Nasdaq climbed 1.52% to 19,701.21, and the Dow Jones added 0.8%, closing at 42,515.09, supported in part by gains across the banking sector.

Supernus Pharmaceuticals (Nasdaq: SUPN) is to buy Sage Therapeutics (Nasdaq: SAGE) for total consideration of around $795 million. Shares in Sage shot up by 35% amid the news by midday Monday, while ...